Literature DB >> 21704587

RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage.

A Kathleen McClendon1, Jeffry L Dean, Adam Ertel, Zhiyan Fu, Dayana B Rivadeneira, Christopher A Reed, Ryan J Bourgo, Agnieszka Witkiewicz, Sankar Addya, Christopher N Mayhew, H Leighton Grimes, Paolo Fortina, Erik S Knudsen.   

Abstract

BACKGROUND & AIMS: The tumor suppressors retinoblastoma (RB) and p53 are important regulators of the cell cycle. Although human cancer cells inactivate RB and p53 by many mechanisms, the cooperative roles of these proteins in tumorigenesis are complex and tissue specific. We analyzed the cooperation of RB and p53 in liver development and pathogenesis of hepatocellular carcinoma.
METHODS: Spontaneous and carcinogen-induced (diethylnitrosamine) tumorigenesis were studied in mice with liver-specific deletions of Rb and/or p53 (Rbf/f;albcre+, p53f/f;albcre+ and Rbf/f; p53f/f;albcre+ mice). Genotype, histologic, immunohistochemical, microarray, quantitative polymerase chain reaction, immunoblot, and comparative genomic hybridization analyses were performed using normal and tumor samples. Comparative microarray analyses were performed against publicly available human microarray data sets.
RESULTS: Deletion of RB and p53 from livers of mice deregulated the transcriptional programs associated with human disease. These changes were not sufficient for spontaneous tumorigenesis; potent quiescence mechanisms compensated for loss of these tumor suppressors. In response to hepatocarcinogen-induced damage, distinct and cooperative roles of RB and p53 were revealed; their loss affected cell cycle control, checkpoint response, and genome stability. In damaged tissue, combined loss of RB and p53 resulted in early lesion formation, aggressive tumor progression, and gene expression signatures and histologic characteristics of advanced human hepatocellular carcinoma.
CONCLUSIONS: The effects RB and p53 loss are determined by the tissue environment; cell stresses that promote aggressive disease reveal the functions of these tumor suppressors.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21704587      PMCID: PMC4562673          DOI: 10.1053/j.gastro.2011.06.046

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  37 in total

1.  Lack of Rb and p53 delays cerebellar development and predisposes to large cell anaplastic medulloblastoma through amplification of N-Myc and Ptch2.

Authors:  Olga Shakhova; Carly Leung; Erwin van Montfort; Anton Berns; Silvia Marino
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

Review 2.  Chromosomal instability and human hepatocarcinogenesis.

Authors:  N Nishida; T Nishimura; T Ito; T Komeda; Y Fukuda; K Nakao
Journal:  Histol Histopathol       Date:  2003-07       Impact factor: 2.303

3.  Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.

Authors:  Zhe Jiang; Tao Deng; Robert Jones; Huiqin Li; Jason I Herschkowitz; Jeff C Liu; Victor J Weigman; Ming-Sound Tsao; Timothy F Lane; Charles M Perou; Eldad Zacksenhaus
Journal:  J Clin Invest       Date:  2010-08-02       Impact factor: 14.808

4.  Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer.

Authors:  Zongxiang Zhou; Andrea Flesken-Nikitin; David C Corney; Wei Wang; David W Goodrich; Pradip Roy-Burman; Alexander Yu Nikitin
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

5.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

Authors:  J Jonkers; R Meuwissen; H van der Gulden; H Peterse; M van der Valk; A Berns
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

Review 6.  Environmental factors and risk for hepatocellular carcinoma.

Authors:  Mimi C Yu; Jian-Min Yuan
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

7.  Elimination of C/EBPalpha through the ubiquitin-proteasome system promotes the development of liver cancer in mice.

Authors:  Guo-Li Wang; Xiurong Shi; Simon Haefliger; Jingling Jin; Angela Major; Polina Iakova; Milton Finegold; Nikolai A Timchenko
Journal:  J Clin Invest       Date:  2010-07       Impact factor: 14.808

Review 8.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

9.  Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage.

Authors:  Seth D Berman; Eliezer Calo; Allison S Landman; Paul S Danielian; Emily S Miller; Julie C West; Borel Djouedjong Fonhoue; Alicia Caron; Roderick Bronson; Mary L Bouxsein; Siddhartha Mukherjee; Jacqueline A Lees
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-12       Impact factor: 11.205

10.  Dose-dependent alterations in gene expression in mouse liver induced by diethylnitrosamine and ethylnitrosourea and determined by quantitative real-time PCR.

Authors:  Takashi Watanabe; Gotaro Tanaka; Shuichi Hamada; Chiaki Namiki; Takayoshi Suzuki; Madoka Nakajima; Chie Furihata
Journal:  Mutat Res       Date:  2008-11-21       Impact factor: 2.433

View more
  17 in total

1.  Modification of the DNA damage response by therapeutic CDK4/6 inhibition.

Authors:  Jeffry L Dean; A Kathleen McClendon; Erik S Knudsen
Journal:  J Biol Chem       Date:  2012-06-25       Impact factor: 5.157

2.  Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery.

Authors:  Brian I Carr; Aldo Cavallini; Catia Lippolis; Rosalba D'Alessandro; Caterina Messa; Maria G Refolo; Angela Tafaro
Journal:  J Cell Physiol       Date:  2013-02       Impact factor: 6.384

Review 3.  Endoreplication and polyploidy: insights into development and disease.

Authors:  Donald T Fox; Robert J Duronio
Journal:  Development       Date:  2013-01-01       Impact factor: 6.868

Review 4.  Mechanisms of hepatocarcinogenesis in chronic hepatitis C.

Authors:  Jonathan K Mitchell; David R McGivern
Journal:  Hepat Oncol       Date:  2014-09-09

Review 5.  The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy.

Authors:  Erik S Knudsen; Purva Gopal; Amit G Singal
Journal:  Am J Pathol       Date:  2013-12-31       Impact factor: 4.307

6.  Ccne1 Overexpression Causes Chromosome Instability in Liver Cells and Liver Tumor Development in Mice.

Authors:  Khaled Aziz; Jazeel F Limzerwala; Ines Sturmlechner; Erin Hurley; Cheng Zhang; Karthik B Jeganathan; Grace Nelson; Steve Bronk; Raul O Fierro Velasco; Erik-Jan van Deursen; Daniel R O'Brien; Jean-Pierre A Kocher; Sameh A Youssef; Janine H van Ree; Alain de Bruin; Hilda van den Bos; Diana C J Spierings; Floris Foijer; Bart van de Sluis; Lewis R Roberts; Gregory J Gores; Hu Li; Jan M van Deursen
Journal:  Gastroenterology       Date:  2019-03-13       Impact factor: 22.682

7.  RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.

Authors:  Erik S Knudsen; A Kathleen McClendon; Jorge Franco; Adam Ertel; Paolo Fortina; Agnieszka K Witkiewicz
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

8.  Organ size control is dominant over Rb family inactivation to restrict proliferation in vivo.

Authors:  Ursula Ehmer; Anne-Flore Zmoos; Raymond K Auerbach; Dedeepya Vaka; Atul J Butte; Mark A Kay; Julien Sage
Journal:  Cell Rep       Date:  2014-07-10       Impact factor: 9.423

9.  RB tumor suppressive function in response to xenobiotic hepatocarcinogens.

Authors:  Christopher Reed; Jack Hutcheson; Christopher N Mayhew; Agnieszka K Witkiewicz; Erik S Knudsen
Journal:  Am J Pathol       Date:  2014-04-13       Impact factor: 4.307

10.  Skp2 deletion unmasks a p27 safeguard that blocks tumorigenesis in the absence of pRb and p53 tumor suppressors.

Authors:  Hongling Zhao; Frederick Bauzon; Hao Fu; Zhonglei Lu; Jinhua Cui; Keiko Nakayama; Keiich I Nakayama; Joseph Locker; Liang Zhu
Journal:  Cancer Cell       Date:  2013-11-11       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.